Expression of Circadian Clock Genes in Human Colorectal Cancer Tissues Using Droplet Digital PCR

References

• Touitou Y, Haus E. Biologic rhythms in clinical and laboratory medicine. Berlin (Heidelberg): Springer; 1992. doi:10.1007/978-3-642-78734-8
   Google Scholar
• Krugluger W, Brandstaetter A, Kallay E, Schueller J, Krexner E, Kriwanek S, et al. Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Cancer Res. 2007;67(16):7917–7922. doi:10.1158/0008-5472.CAN-07-0133
   PubMed Web of Science ®Google Scholar
• Wang Y, Hua L, Lu C, Chen Z. Expression of circadian clock gene human Period2 (hPer2) in human colorectal carcinoma. World J Surg Onc. 2011;9(1):166. doi:10.1186/1477-7819-9-166.
   PubMedGoogle Scholar
• Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst. 2001;93(20):1563–1568. doi:10.1093/jnci/93.20.1563.
   PubMedGoogle Scholar
• Erren TC, Pape HG, Reiter RJ, Piekarski C. Chronodisruption and cancer. Naturwissenschaften. 2008;95(5):367–382. doi:10.1007/s00114-007-0335-y
   PubMedGoogle Scholar
• Kamdar BB, Tergas AI, Mateen FJ, Bhayani NH, Oh J. Night-shift work and risk of breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;138(1):291–301. doi:10.1007/s10549-013-2433-1.
   PubMed Web of Science ®Google Scholar
• Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6(8):3038–3045. Retrieved from http://clincancerres.aacrjournals.org/
   PubMed Web of Science ®Google Scholar
• Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111(1):41–50. doi:10.1016/S0092-8674(02)00961-3
   PubMed Web of Science ®Google Scholar
• Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene Per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22(3):375–382. doi:10.1016/j.molcel.2006.03.038
   PubMed Web of Science ®Google Scholar
• Day E, Dear PH, McCaughan F. Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine. Methods. 2013;59(1):101–107. doi:10.1016/j.ymeth.2012.08.001.
   PubMed Web of Science ®Google Scholar
• Bio-Rad Laboratories Inc., droplet digital PCR applications guide. Hercules: Bio-Rad Laboratories Inc.; 2014. Available from: http://www.bio-rad.com/
   Google Scholar
• Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, et al. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 2011;28(10):841–851. doi:10.3109/07420528.2011.615182.
   PubMed Web of Science ®Google Scholar
• Oshima T, Takenoshita S, Akaike M, Kunisaki C, Fujii S, Nozaki A, et al. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep. 2011;25(5):1439–1446. doi:10.3892/or.2011.1207
   PubMed Web of Science ®Google Scholar
• Wang X, Yan D, Teng M, Fan J, Zhou C, Li D, et al. Reduced expression of PER3 is associated with incidence and development of colon cancer. Ann Surg Oncol. 2012;19(9):3081–3088. doi:10.1245/s10434-012-2279-5
   PubMed Web of Science ®Google Scholar
• Karantanos T, Theodoropoulos G, Gazouli M, Vaiopoulou A, Karantanou C, Lymberi M, et al. Expression of clock genes in patients with colorectal cancer. Int J Biol Markers. 2013;28(3):280–285. doi:10.5301/JBM.5000033
   PubMed Web of Science ®Google Scholar
• Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005;26(7):1241–1246. doi:10.1093/carcin/bgi075
   PubMed Web of Science ®Google Scholar
• Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL. Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia. 2007;9(10):797–800. doi:10.1593/neo.07595.
   PubMed Web of Science ®Google Scholar
• Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL, Lin SF, et al. Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol. 2005;206(1):111–120. doi:10.1002/path.1756.
   PubMed Web of Science ®Google Scholar
• Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, et al. A role for the clock gene Per1 in prostate cancer. Cancer Res. 2009;69(19):7619–7625. doi:10.1158/0008-5472.CAN-08-4199
   PubMed Web of Science ®Google Scholar
• Pogue-Geile KL, Lyons-Weiler J, Whitcomb DC. Molecular overlap of fly circadian rhythms and human pancreatic cancer. Cancer Lett. 2006;243(1):55–57. doi:10.1016/j.canlet.2005.11.049.
   PubMed Web of Science ®Google Scholar
• Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood. 2005;106(8):2827–2836. doi:10.1182/blood-2005-01-0358
   PubMed Web of Science ®Google Scholar
• Kuo SJ, Chen ST, Yeh KT, Hou MF, Chang YS, Hsu NC, Chang JG. Disturbance of circadian gene expression in breast cancer. Virchows Arch. 2009;454(4):467–474. doi:10.1007/s00428-009-0761-7
   PubMed Web of Science ®Google Scholar
• Koyanagi S, Kuramoto Y, Nakagawa H, Aramaki H, Ohdo S, Soeda S, et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 2003;63(21):7277–7283. Retrieved from http://cancerres.aacrjournals.org/
   PubMed Web of Science ®Google Scholar
• Wang L, Chen B, Wang Y, Sun N, Lu C, Qian R, et al. hClock gene expression in human colorectal carcinoma. Mol Med Rep. 2013;8(4):1017–1022. doi:10.3892/mmr.2013.1643
   PubMed Web of Science ®Google Scholar
• Alhopuro P, Bjorklund M, Sammalkorpi H, Turunen M, Tuupanen S, Bistrom M, et al. Mutations in the circadian gene CLOCK in colorectal cancer. Mol Cancer Res. 2010;8(7):952–960. doi:10.1158/1541-7786.MCR-10-0086
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Jordan RCK, Wood PA, Li Q, Lincoln DW, Sothern RB, et al. Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol. 2001;158(5):1793–1801. doi:10.1016/S0002-9440(10)64135-1
   PubMed Web of Science ®Google Scholar
• Griniatsos J, Michail OP, Theocharis T, Arvelakis A, Papaconstantinou I, Felekouras E, et al. Circadian variation in expression of G1 phase cyclins D1 and E and cyclin-dependent kinase inhibitors p16 and p21 in human bowel mucosa. World J Gastroenterol. 2006;12(13):2109–2114. doi:10.3748/wjg.v12.i13.2109.
   PubMed Web of Science ®Google Scholar
• Mao Y, Fu A, Hoffman AE, Jacobs DI, Jin M, Chen K, et al. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications. Tumor Biol. 2015;36(5):3533–3539. doi:10.1007/s13277-014-2989-3.
   PubMedGoogle Scholar
• Bhat S, Herrmann J, Armishaw P, Corbisier P, Emslie KR. Single molecule detection in nanofluidic digital array enables accurate measurement of DNA copy number. Anal Bioanal Chem. 2009;394(2):457–467. doi:10.1007/s00216-009-2729-5.
   PubMed Web of Science ®Google Scholar
• Bhat S, McLaughlin JLH, Emslie KR. Effect of sustained elevated temperature prior to amplification on template copy number estimation using digital polymerase chain reaction. Analyst. 2011;136(4):724–732. doi:10.1039/C0AN00484G.
   PubMed Web of Science ®Google Scholar
• Wood PA, Yang X, Taber A, Oh EY, Ansell C, Ayers SE, et al. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res. 2008;6(11):1786–1793. doi:10.1158/1541-7786.MCR-08-0196.
   PubMed Web of Science ®Google Scholar
• Soták M, Polidarová L, Ergang P, Sumová A, Pácha J. An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors. Int J Cancer. 2013;132(5):1032–1041. doi:10.1002/ijc.27760.
   PubMed Web of Science ®Google Scholar
• Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 2003;97(1):155–169. doi:10.1002/cncr.11040.
   PubMed Web of Science ®Google Scholar
• Lis CG, Grutsch JF, Wood P, You M, Rich I, Hrushesky WJ. Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther. 2003;2(2):105–111. doi:10.1177/1534735403002002002.
   PubMedGoogle Scholar
• Kobayashi M, Wood P, Hrushesky W. Circadian chemotherapy for gynecological and genitourinary cancers. Chronobiol Int. 2002;19(1):237–251. doi:10.1081/CBI-120002600.
   PubMed Web of Science ®Google Scholar
• Altinok A, Lévi F, Goldbeter A. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci. 2009;36(1):20–38. doi:10.1016/j.ejps.2008.10.024.
   PubMed Web of Science ®Google Scholar
• Gorbacheva V, Kondratov R, Zhang R, Cherukuri S, Gudkov A, Takahashi J, et al. From the cover: circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A. 2005;102(9):3407–3412. doi:10.1073/pnas.0409897102.
   PubMed Web of Science ®Google Scholar